AstraZeneca shareholders question Pfizer deal
UK drugs company AstraZeneca has rejected an improved "final" takeover offer from US drugs giant Pfizer.
Pfizer had made a new offer of £55 per share, valuing AstraZeneca at about £69bn.
Aberdeen Asset Management's Anne Richards told BBC News about some of the shareholders' reaction to the latest bid rejection.
19 May 2014
- From the section Business